Supplementary Figure 5: Induction of cell death in SCLC cells after treatment with related TCAs and with specific GPCR inhibitors.

A-B, MTT viability assay of mouse (Kp1 and Kp3) and human (H187 and H82) SCLC cell lines following treatment with 50µM imipramine (Imip) and increasing doses of the related TCAs desipramine (A) and amitriptyline (B) at 2% serum and for 48 hours (n=3 independent experiments). C-H, MTT viability assays of cells cultured at 2% serum (n≥3 independent experiments) and treated with the H1R antagonist azelastine (C), the CHRM3 antagonist 4-DAMP (D), the HTR2 antagonist ritanserin (E), in comparison to treatment with 30µM promethazine (Prom) and 50µM imipramine (Imip) for 48 hours and with increasing doses of the specific H1R ligand 2-(2-Pyridil)-ethyamine (PEA) (F), acetylcholine (Ace) (G), and serotonin (Ser) (H), in the absence or presence of 50µM imipramine (Imip) and 30µM promethazine (Prom) for 24 hours. The paired t-test was used to calculate the p-values of each ligand, imipramine- and promethazine- treated cells versus control cells and of imipramine- and promethazine- treated cells versus ligand- treated cells combined with imipramine or promethazine.